|
1.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2.
|
Berry DA, Cronin KA, Plevritis SK, Fryback
DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD and
Feuer EJ; Cancer Intervention and Surveillance Modeling Network
(CISNET) Collaborators: Effect of screening and adjuvant therapy on
mortality from breast cancer. N Engl J Med. 353:1784–1792. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Cardoso F, Bedard PL, Winer EP, Pagani O,
Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T
and Albain KS: ESO-MBC Task Force, International guidelines for
management of metastatic breast cancer: combination vs. sequential
single-agent chemotherapy. J Natl Cancer Inst. 101:1174–1181. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Schneider BP, Winer EP, Foulkes WD, Garber
J, Perou CM, Richardson A, Sledge GW and Carey LA: Triple-negative
breast cancer: risk factors to potential targets. Clin Cancer Res.
14:8010–8018. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Anders CK and Carey LA: Biology,
metastatic patterns, and treatment of patients with triple-negative
breast cancer. Clin Cancer Res. 9:S73–S81. 2009.PubMed/NCBI
|
|
8.
|
Elias AD: Triple-negative breast cancer: a
short review. Am J Clin Oncol. 33:637–645. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Rodríguez-Paredes M and Manel Esteller M:
Cancer epigenetic reaches mainstream oncology. Nat Med. 17:330–339.
2011.PubMed/NCBI
|
|
10.
|
Sawan C, Vaissière T, Murr R and Herceg Z:
Epigenetic drivers and genetic passengers on the road to cancer.
Mutat Res. 642:1–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ellis L, Atadja PW and Johnstone RW:
Epigenetics in cancer: targeting chromatin modifications. Mol
Cancer Ther. 8:1409–1420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Wong ST: Emerging treatment combinations:
integrating therapy into clinical practice. Am J Health Syst Pharm.
66:S9–S14. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Göttlicher M, Minucci S, Zhu P, Krämer OH,
Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG
and Heinzel T: Valproic acid defines a novel class of HDAC
inhibitors inducing differentiation of transformed cells. EMBO J.
20:6969–6978. 2001.
|
|
14.
|
Hodges-Gallagher L, Valentine CD, Bader SE
and Kushner PJ: Inhibition of histone deacetylase enhances the
anti-proliferative action of antiestrogens on breast cancer cells
and blocks tamoxifen-induced proliferation of uterine cells. Breast
Cancer Res Treat. 105:297–309. 2007. View Article : Google Scholar
|
|
15.
|
Fortunati N, Bertino S, Costantino L,
Bosco O, Vercellinatto I, Catalano MG and Boccuzzi G: Valproic acid
is a selective antiproliferative agent in estrogen-sensitive breast
cancer cells. Cancer Lett. 259:156–164. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Fortunati N, Catalano MG, Marano F, Mugoni
V, Pugliese M, Bosco O, Mainini F and Boccuzzi G: The pan-DAC
inhibitor LBH589 is a multi-functional agent in breast cancer
cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
Breast Cancer Res Treat. 124:667–675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Hajra KM, Ji X and Fearon ER: Extinction
of E-cadherin expression in breast cancer via a dominant repression
pathway acting on proximal promoter elements. Oncogene.
18:7274–7279. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Fortunati N, Bertino S, Costantino L, De
Bortoli M, Compagnone A, Bandino A, Catalano MG and Boccuzzi G:
Valproic acid restores ER alpha and antiestrogen sensitivity to ER
alpha-negative breast cancer cells. Mol Cell Endocrinol. 314:17–22.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Katzenellenbogen BS and Frasor J:
Therapeutic targeting in the estrogen receptor hormonal pathway.
Semin Oncol. 31:28–38. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Ring A and Dowsett M: Mechanisms of
tamoxifen resistance. Endocr Relat Cancer. 11:643–658. 2004.
View Article : Google Scholar
|
|
21.
|
Jovanovic J, Rønneberg JA, Tost J and
Kristensen V: The epigenetics of breast cancer. Mol Oncol.
4:242–254. 2010. View Article : Google Scholar
|
|
22.
|
Zhou Q, Atadja P and Davidson NE: Histone
deacetylase inhibitor LBH589 reactivates silenced estrogen receptor
alpha (ER) gene expression without loss of DNA hypermethylation.
Cancer Biol Ther. 6:64–69. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Fiskus W, Ren Y, Mohapatra A, Bali P,
Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J and Bhalla K:
Hydroxamic acid analogue histone deacetylase inhibitors attenuate
estrogen receptor-alpha levels and transcriptional activity: a
result of hyperacetylation and inhibition of chaperone function of
heat shock protein 90. Clin Cancer Res. 13:4882–4890. 2007.
View Article : Google Scholar
|
|
24.
|
Hayashi A, Horiuchi A, Kikuchi N, Hayashi
T, Fuseya C, Suzuki A, Konishi I and Shiozawa T: Type-specific
roles of histone deacetylase (HDAC) overexpression in ovarian
carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates
cell migration with downregulation of E-cadherin. Int J Cancer.
127:1332–1346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelialmesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Lombaerts M, van Wezel T, Philippo K,
Dierssen JWF, Zimmerman RME, Oosting J, van Eijk R, Eilers PH, van
De Water B, Cornelisse CJ and Cleton-Jansen AM: E-cadherin
transcriptional downregulation by promoter methylation but not
mutation is related to epithelial-to-mesenchymal transition in
breast cancer cell lines. Br J Cancer. 94:661–671. 2006.PubMed/NCBI
|
|
27.
|
Nam JS, Ino Y, Kanai Y, Sakamoto M and
Hirohashi S: 5-Aza-2′-deoxycytidine restores the E-cadherin system
in E-cadherin-silenced cancer cells and reduces cancer metastasis.
Clin Exp Metastasis. 21:49–56. 2004.
|
|
28.
|
Blanco MJ, Moreno-Bueno G, Sarrio D,
Locascio A, Cano A, Palacios J and Nieto MA: Correlation of Snail
expression with histological grade and lymph node status in breast
carcinomas. Oncogene. 21:3241–3246. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT,
Wu CW and Shen CY: Mechanisms of inactivation of E-cadherin in
breast carcinoma: modification of the two-hit hypothesis of tumor
suppressor gene. Oncogene. 20:3814–3823. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Elloul S, Elstrand MB, Nesland JM, Trope
CG, Kvalheim G, Goldberg I, Reich R and Davidson B: Snail, Slug,
and Smad-interacting protein 1 as novel parameters of disease
aggressiveness in metastatic ovarian and breast carcinoma. Cancer.
103:1631–1643. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Rosivatz E, Becker I, Specht K, Fricke E,
Luber B, Busch R, Hofler H and Becker KF: Differential expression
of the epithelialmesenchymal transition regulators Snail, SIP1, and
Twist in gastric cancer. Am J Pathol. 161:1881–1891. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Fearon ER: Connecting estrogen receptor
function, transcriptional repression, and E-cadherin expression in
breast cancer. Cancer Cell. 3:307–310. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Fujita N, Jaye DL, Kajita M, Geigerman C,
Moreno CS and Wade PA: MTA3, a Mi-2/NuRD complex subunit, regulates
an invasive growth pathway in breast cancer. Cell. 113:207–219.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Catalano MG, Pugliese M, Gargantini E,
Grange C, Bussolati B, Asioli S, Bosco O, Poli R, Compagnone A,
Bandino A, Mainini F, Fortunati N and Boccuzzi G: Cytotoxic
activity of the histone deacetylase inhibitor Panobinostat (LBH589)
in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer.
130:694–704. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Maiso P, Carvajal-Vergara X, Ocio EM,
López-Pérez R, Mateo G, Gutiérrez N, Atadja P, Pandiella A and San
Miguel JF: The histone deacetylase inhibitor LBH589 is a potent
antimyeloma agent that overcomes drug resistance. Cancer Res.
66:5781–5789. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Shao W, Growney JD, Feng Y, O’Connor G, Pu
M, Zhu W, Yao YM, Kwon P, Fawell S and Atadja P: Activity of
deacetylase inhibitor Panobinostat (LBH589) in cutaneous T-cell
lymphoma models: defining molecular mechanisms of resistance. Int J
Cancer. 127:2199–2208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Tate CR, Rhodes LV, Segar HC, Driver JL,
Pounder FN, Burow ME and Collins-Burow BM: Targeting
triple-negative breast cancer cells with the histone deacetylase
inhibitor panobinostat. Breast Cancer Res. 14:R792012. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Keen JC, Yan L, Mack KM, Pettit C, Smith
D, Sharma D and Davidson NE: A novel histone deacetylase inhibitor,
scriptaid, enhances expression of functional estrogen receptor
alpha (ER) in ER negative human breast cancer cells in combination
with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat. 81:177–186.
2003.PubMed/NCBI
|
|
40.
|
Sharma D, Saxena NK, Davidson NE and
Vertino PM: Restoration of tamoxifen sensitivity in estrogen
receptor-negative breast cancer cells: tamoxifen-bound reactivated
ER recruits distinctive corepressor complexes. Cancer Res.
66:6370–6378. 2006. View Article : Google Scholar
|
|
41.
|
Peinado H, Ballestar E, Esteller M and
Cano A: Snail mediates E-cadherin repression by the recruitment of
the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell
Biol. 24:306–319. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Kim IA, No M, Lee JM, Shin JH, Oh JS, Choi
EJ, Kim IH, Atadja P and Bernhard EJ: Epigenetic modulation of
radiation response in human cancer cells with activated EGFR or
HER-2 signaling: potential role of histone deacetylase 6. Radiother
Oncol. 92:125–132. 2009. View Article : Google Scholar : PubMed/NCBI
|
